Previous Close | 99.99 |
Open | 99.97 |
Bid | 0.00 x 800 |
Ask | 0.00 x 3200 |
Day's Range | 99.97 - 100.00 |
52 Week Range | 45.50 - 100.00 |
Volume | |
Avg. Volume | 1,472,638 |
Market Cap | 6.156B |
Beta (5Y Monthly) | 0.55 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -9.72 |
Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 97.86 |
Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.
Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.
PARK CITY, Utah, February 23, 2022--Arena Pharmaceuticals today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021